Text Size

A A A

Search


 

 

CHAIRMAN LEVEL

EXECUTIVE LEVEL

DIRECTOR LEVEL

National Stroke Association's mission to reduce the incidence and impact of stroke is enabled by the generous support of our Corporate Alliance Board (CAB), an elite group of industry partners with a mutual interest in stroke awareness and prevention.

Through Corporate Alliance sponsorship and grants, National Stroke Association develops educational programs about all aspects of stroke for the general public, medical professionals, and those touched personally by stroke.

National Stroke Association thanks our CAB members for their dedication to National Stroke Association's mission.

We invite you to join National Stroke Association in our efforts to reduce the incidence and impact of stroke by becoming a member of our Corporate Alliance Board.  Distinct levels of sponsorship allow you to select a commitment that is consistent with your goals and resources.

For more information about becoming a CAB partner, please contact any of the following:

Sharon Januchowski

Jamie Charbonneau

sjanuchowski@stroke.org

jcharbonneau@stroke.org

303-754-0946

303-754-0943

View our Corporate Alliance Policy

CHAIRMAN LEVEL

Allergan, Inc

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Bristol-Myers Squibb Pfizer Inc partnership logo

Bristol-Myers Squibb/Pfizer Inc Partnership

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Pfizer Inc is committed to helping people improve their health by discovering and developing medicines, as well as informing consumers and health care providers about our medicines and the medical conditions they treat. Through multiple initiatives, Pfizer aims to ensure access to treatments and educate, empower and motivate consumers to take the necessary steps to lead longer, healthier, happier lives.  For more information about Pfizer's patient assistance programs, visit http://www.pfizerhelpfulanswers.com/.

 

Back to top

EXECUTIVE LEVEL

Boehringer Ingelheim Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc. discovers, develops and markets innovative and unique medications for the treatment of respiratory, cardiovascular, immunological and central nervous system diseases. BIPI is the maker of Aggrenox (aspirin and extended-release dipyridamole), approved in 1999 as an antiplatelet agent for the treatment of stroke and TIA.

Boehringer Ingelheim
  
Genentech, Inc.

For over a decade, Genentech has been committed to advancing the treatment of stroke. In 1995, the company's t-PA, Activase® (Alteplase) was approved for reducing disability and improving recovery following acute ischemic stroke. Now, more than 60,000 eligible stroke patients have been treated. Genentech also supports numerous educational programs for healthcare professionals caring for stroke patients. For information on these resources please contact 1-88-TX-STROKE or visit http://www.activase.com/.

Genentech
 
Medtronic, Inc.

Medtronic is the global leader in medical technology alleviating pain, restoring health and extending life for millions of people around the world. The company’s product and therapy portfolio includes intrathecal therapy for the management of severe spasticity associated with multiple sclerosis, cerebral palsy, stroke, brain injury, or spinal cord injury. For more information please visit http://www.medtronic.com/ or http://www.yourlifeafterstroke.com/

Medtronic Logo

back to top 

DIRECTOR LEVEL

Avanir Pharmaceuticals, Inc.

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. We are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir has an investigational drug in development for pseudobulbar affect (PBA), a neurologic condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA occurs in patients with underlying neurologic disease or injury, including stroke. For more information about AVANIR, please visit www.avanir.com.

Avanir Pharmaceuticals logo

 
Bioness, Inc.

Bioness is the leading provider of innovative technologies to help people regain mobility and independence and improve quality of life. Neurological solutions for people suffering from hand and lower extremity paralysis include the L300® Foot Drop System, L300® Plus System, and the H200® Wireless Hand Rehabilitation System which utilize functional electrical stimulation (FES) to promote motor recovery and function for individuals affected by central nervous system disorders including stroke.

 Bioness logo
H. Lundbeck A/S

H. Lundbeck A/S is an international Danish pharmaceutical company founded in 1915 and is headquartered in Denmark. Today Lundbeck employs approximately 5,900 people worldwide. As a research based company, every year Lundbeck invests around 20 percent of its revenue in the research and development of new innovative drugs, which will improve the treatment of the millions of people suffering from brain disorders all over the world. In total the company employs around 1,200 highly qualified and specialized employees in our research and development departments. As part of Lundbeck's commitment to improve the health of patients, Greta Lundbeck founded the Lundbeck Institute in 1954 with the aim to increase awareness, and management of CNS related disorders. The Lundbeck International Neuroscience Foundation (LINF) was established with the aim to educate medical professionals in CNS related conditions such as stroke. For more information, please visit: http://lundbeck.com

Image of Lundbeck logo
Janssen Pharmaceuticals, Inc.

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.  Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on the people's lives, and we aim to empower people through disease awareness, education and access to quality care. Our research and development strategy focuses on identifying the medical needs, and harnessing the best science in the world, whether from our own laboratories, or through strategic relationships and collaborations. For more information visit http://www.janssen.com/our-companies.html or http://www.afibonetoone.com/

Janssen Pharmaceutical logo

Grants and sponsorships enable many of our education programs for healthcare professionals, stroke survivors and caregivers, and the at-risk public. National Stroke Association gratefully acknowledges our 2013 Grants and Sponsorships.

Back to Top

Get Involved

Stroke and You

Subscribe to StrokeSmart Now

National Stroke Association

1-800-STROKES
1-800-787-6537
9707 E. Easter Lane, Suite B
Centennial, CO 80112
info@stroke.org

Stroke Help Line logo